Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Abstract: Analogs of PPAR5 and analogs of 20-OH-PGE2, which are PPAR5 agonists and 20-OH-PGE2 antagonists, respectively, and methods of using the same for inducing osteogenesis or chondrogenesis, are disclosed.

Abstract: Analogs of PPAR5 and analogs of 20-OH-PGE2, which are PPAR5 agonists and 20-OH-PGE2 antagonists, respectively, and methods of using the same for inducing osteogenesis or chondrogenesis, are disclosed.

Abstract: The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered.

Abstract: A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds are rapidly metabolized to inactive and non-toxic metabolites when exposure to the modified compounds is halted.

Abstract: Methods and compositions for treating cancer patients that include administering at least one or more hybrid derivatives of paclitaxel that simultaneously display improved aqueous solubility, chemical stability under physiological conditions, a decreased liability toward multi-drug resistance, and in certain instances enhanced selective toxicity toward cancer cells compared to normal cells. The derivative, paclitaxel substituted with at least one or more polar appendages at either the 7- or 10-positions as defined by a formula “7-OR-10-OR?-paclitaxel”, is either deployed alone or in combination protocols with other chemotherapeutic agents.

Abstract: A cookware assembly includes an open-top vessel with diametrically opposed handles and diametrically opposed pour spouts, and a lid including an outer peripheral frame member, a central member spaced from the frame member and support structure coupled to each of the frame member and the central member closing the space therebetween. A flange depends from the frame member and has a plurality of vertically elongated apertures therethrough adjacent to a predetermined location on the frame which carries indicia to indicate the location of the apertures.